D2S Pharma
ActiveFrom the official registers: KBO 10 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
D2S Pharma has been active since 2014 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €424,697 and a net result of €38,474. Equity has been growing by about 14% per year since 2019. Its solvency ranks better than 80% of 62 sector peers (NACE 21, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Official details
KBO- Status
- Active since 30-09-2014 Normal situation
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparations NACE 21100and 3 others
- Establishment unit
- 2.235.656.394 9700 Oudenaarde, since 30-09-2014
- Financial year end
- 30 June
- Peppol
- Reachable since 12-12-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
- Gross margin
- €129,195
- ▲ 16.3%
- Turnover
- ≈ €330,000
- estimated
- Profit
- €38,474
- ▲ 117%
- Equity
- €424,697
- ▲ 10.0%
- Total assets
- €582,318
- ▲ 8.6%
- Staff
- 0.5 FTE
- ▼ 16.7%
Score breakdownlowers riskLiquidity: current ratio 5.11, cash €188,504Equity €424,697 (72.9% of total assets)Founded in 2014Figures for financial year 2025 (filed on 25-02-2026)Show the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 21, micro). It does better than 77% of them on solvency, 83% on liquidity, 69% on profitability and 62% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 7 days before the deadline. In the sector (NACE 21), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
Key points
Comparable companies
These companies have the same main activity as D2S Pharma: manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100). They are comparable in size and age: total assets between €383,000 and €1m, founded between 2005 and 2018.
| Company | Total assets | Gross margin |
|---|---|---|
| D2S Pharma Oudenaarde | €0.6m | €0.1m |
| Pharmacie BIHAIN Trois-Ponts | €0.6m | €0.2m |
| VDP AUTOMATION Hasselt | €0.5m | €0.1m |
| SOBEGAPHARMA Mons | €1.0m | €0.2m |
| XeroThera Europe Liège | €0.8m | €0.2m |
| MY HEALTH INTERNATIONAL Lummen | €1.0m | €0.7m |
| PHARMACIE DES PAGODES Genappe | €0.4m | €0.2m |
Documents
Annual accounts at the NBB
- Annual accounts 2025filed on 20-02-2026
- Annual accounts 2024filed on 07-01-2025
- Annual accounts 2023filed on 09-02-2024
- Annual accounts 2022filed on 25-01-2023
Acts in the Belgian Official Gazette
All publications in the Belgian Official GazetteArticles and registers
- Coordinated articles of associationnotaries' database
- Entry in the KBO registerKBO Public Search
Key facts about D2S Pharma
- What is the company number of D2S Pharma?
- The company number of D2S Pharma is 0563.446.868. The VAT number is the same number with BE in front: BE 0563.446.868.
- Where is D2S Pharma based?
- The registered office is at Berchemweg 139, 9700 Oudenaarde.Company details
- What does D2S Pharma do?
- According to the KBO register, the main activity is manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21100).
- What is the legal form of D2S Pharma?
- The legal form of D2S Pharma is Private limited company (BV).
- When was D2S Pharma founded?
- D2S Pharma was founded on 30-09-2014.
- Is D2S Pharma still active?
- Yes, D2S Pharma is an active enterprise in the KBO register.
- How many employees does D2S Pharma have?
- D2S Pharma had an average of 0.5 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of D2S Pharma?
- The turnover in financial year 2025 is ≈ €330,000. This figure is estimated from the gross margin of €129,195 and 1,644 comparable companies of the same size. It probably lies between €200,000 and €610,000. It is a rough estimate.
- Is D2S Pharma profitable?
- In financial year 2025, D2S Pharma made a profit of €38,474.
- Where can I find the annual accounts of D2S Pharma?
- D2S Pharma filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts 2025 (PDF)
- When are the next annual accounts of D2S Pharma due?
- D2S Pharma must file the annual accounts for financial year 2026 by 31-01-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.